GlassScriptPhysician profile
Ammoura Ibrahim
NPI 1588195911
$425.51
in general payments reported to CMS, 2019-2025
13 companies · $426 in 2025
The $426 reported for 2025 was more than what 85% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $425.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $125.00 | 2025 | Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $49.78 | 2025 | Iclusig, Ninlaro |
| Daiichi Sankyo INC. | $29.69 | 2025 | Enhertu |
| Glaxosmithkline, LLC. | $24.19 | 2025 | Ojjaara |
| Syndax Pharmaceuticals, INC. | $23.69 | 2025 | |
| Invivyd INC | $23.66 | 2025 | Pemgarda |
| Beone Medicines USA, INC. | $23.46 | 2025 | Brukinsa |
| Abbvie INC. | $23.24 | 2025 | |
| Tempus Ai, INC | $21.92 | 2025 | Xt Cdx |
| Janssen Biotech, INC. | $21.08 | 2025 | Darzalex, Talvey |
| Regeneron Healthcare Solutions, INC. | $20.62 | 2025 | Lynozyfic |
| Apellis Pharmaceuticals, INC. | $19.83 | 2025 | |
| Astellas Pharma US INC | $19.35 | 2025 | Vyloy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ammoura Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.